| pubmed-article:8947949 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C0178795 | lld:lifeskim |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C0005854 | lld:lifeskim |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C0005528 | lld:lifeskim |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C0376196 | lld:lifeskim |
| pubmed-article:8947949 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:8947949 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8947949 | pubmed:dateCreated | 1997-3-11 | lld:pubmed |
| pubmed-article:8947949 | pubmed:abstractText | Previous results have shown that treatment of rats with morphine during the neonatal period can influence development of peptide transport system-1 (PTS-1), the blood-brain barrier transport system for Tyr-MIF-1 and methionine enkephalin. Previous work has suggested that the activity level of PTS-1 correlates with the concentration of methionine enkephalin in the brain. We show here that rats treated peripherally with morphine sulfate (MS) in both the prenatal and neonatal periods have enhanced activity of PTS-1. The degree of enhancement increases with age to reach a 66% increase in comparison with controls at age 9 weeks. The mu agonist MS was more powerful than the kappa agonist ethylketocyclazocine (EKC) or the delta agonist [D-Pen2.5,pCl-Phe4]enkephalin (pCl-DPDPE) in producing this effect. Opiate antagonists had complex effects with methylnaltrexone blocking the action of MS on PTS-1. These results show that the level of PTS-1 activity in adult rats can be modified by perinatal events that affect opiate tone during development. | lld:pubmed |
| pubmed-article:8947949 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8947949 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8947949 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8947949 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8947949 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8947949 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8947949 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8947949 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8947949 | pubmed:issn | 0892-0362 | lld:pubmed |
| pubmed-article:8947949 | pubmed:author | pubmed-author:KastinA JAJ | lld:pubmed |
| pubmed-article:8947949 | pubmed:author | pubmed-author:BanksW AWA | lld:pubmed |
| pubmed-article:8947949 | pubmed:author | pubmed-author:HarrisonL MLM | lld:pubmed |
| pubmed-article:8947949 | pubmed:author | pubmed-author:ZadinaJ EJE | lld:pubmed |
| pubmed-article:8947949 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8947949 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:8947949 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8947949 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8947949 | pubmed:pagination | 711-5 | lld:pubmed |
| pubmed-article:8947949 | pubmed:dateRevised | 2009-10-26 | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:meshHeading | pubmed-meshheading:8947949-... | lld:pubmed |
| pubmed-article:8947949 | pubmed:articleTitle | Perinatal treatment of rats with opiates affects the development of the blood-brain barrier transport system PTS-1. | lld:pubmed |
| pubmed-article:8947949 | pubmed:affiliation | Veterans Affairs Medical Center-New Orleans, LA 70146, USA. | lld:pubmed |
| pubmed-article:8947949 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8947949 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
